Endurance Training: Heart Changes in Athletes
Myocardial Fibrosis in Athletes Linked to Increased Ventricular Arrhythmia Risk
A groundbreaking study reveals a significant association between myocardial fibrosis, detected via cardiac MRI, and an elevated risk of ventricular arrhythmias in asymptomatic male endurance athletes.
Key Findings from the Study
A recent prospective study has uncovered a compelling link between the presence of myocardial fibrosis in the heart muscle and an increased likelihood of developing ventricular arrhythmias among healthy, asymptomatic male endurance athletes. The research, which followed participants for a median of 720 days, focused on the primary endpoint of incident ventricular arrhythmia.
Cardiac MRI reveals Widespread Fibrosis
Cardiac Magnetic Resonance (CMR) imaging identified focal myocardial fibrosis in a substantial portion of the athletes studied, with nearly half (47.2%) exhibiting this condition. Importantly,the observed fibrosis was nonischemic in distribution,meaning it was not caused by a lack of blood flow to the heart muscle.The basal inferolateral segment of the left ventricle was the most commonly affected area.
Fibrosis as a Predictor of Arrhythmia
the study’s findings highlight myocardial fibrosis as an independent predictor of ventricular arrhythmia.Athletes with fibrosis demonstrated a significantly higher risk, as indicated by a hazard ratio (HR) of 4.7 (95% CI, 1.8-12.8; P = .002). This association remained robust even after adjusting for left ventricular end-diastolic volume, a measure of the heart’s chamber size.
Other Risk Factors Identified
Beyond fibrosis, the research pointed to other factors associated with an increased risk of ventricular arrhythmia. Athletes experiencing ventricular arrhythmias showed significantly greater left ventricular end-diastolic volumes (113 ± 18 mL/m compared to 106 ± 13 mL/m; P = .04) and longer native T1 times on CMR (1252 ± 46 ms compared to 1241 ± 39 ms; P = .03). Native T1 mapping is a CMR technique that can reflect diffuse myocardial changes.
Furthermore, athletes with myocardial fibrosis were more likely to exhibit premature ventricular contractions (PVCs) during exercise testing than those without fibrosis (71.4% versus 42%; P = .003). These exercise-induced PVCs also tended to have more atypical features in the fibrosis group (46.9% versus 18%; P = .002).
Implications for Clinical Practise
The researchers emphasized that myocardial fibrosis, left ventricular dilatation, and exercise-induced PVCs may collectively serve as indirect predictors of sudden cardiac arrest risk in certain athletic populations. However, they stressed the need for further research to confirm these associations and to investigate whether athletes with CMR-detected myocardial fibrosis might have an undiagnosed form of cardiomyopathy.”In this prospective study, myocardial fibrosis on cardiovascular magnetic resonance imaging was independently associated with the risk of ventricular arrhythmia in healthy, asymptomatic veteran male endurance athletes,” the study authors reported.”Other predictors of ventricular arrhythmia included left ventricular dilatation, and exercise-induced premature ventricular contractions.”
Study Details and Limitations
This significant research was led by Wasim Javed, phd, from the Leeds Institute of Cardiovascular and Metabolic medicine in the United Kingdom. the findings were published online on July 17 in Circulation: Cardiovascular Imaging.
The study authors acknowledged several limitations that warrant consideration. The relatively small sample size and the highly selected nature of the participants mean that the findings may not be generalizable to broader populations, including female athletes or athletes from diverse ethnic backgrounds. Additionally, the use of single-lead implantable loop recorders prevented the precise localization of ventricular arrhythmias to confirm their origin from the site of myocardial fibrosis. The study’s endpoint, ventricular arrhythmia, only indirectly correlates with sudden cardiac death, necessitating further investigation to fully understand the clinical implications.
Funding and Disclosures
The research received support from the National Institute for Health and Care Research Leeds Biomedical Research Center, the British Heart foundation, and the Leeds Clinical Research Facility.
**
This article was generated with the assistance of AI tools and reviewed by human editors prior to publication.*
